Jason B. Bock, PhD

Strategic, visionary leader with over 20 years experience transforming concepts into products for patients in organizations ranging from startups to large global pharmaceuticals.

Highlights

Leadership

- Executive Site leader for multiple locations. Accountable for daily site operations, long term strategic site vision and master planning, development and management of effective site executive leadership teams
- Led sites through various changes including rapid expansion and construction, company acquisitions, site closures and layoffs
- Successfully transitioned employees from a start-up to a large pharmaceutical environment including large geographical relocation with a 90% retention rate of employees for the company

Biologics CMC Development and Manufacturing

- Developed efficient risk-based CMC strategies for novel mAbs and cell therapies with a focus on progressive regulatory principles, reduction of cost of goods, and minimizing cycle time to IND and BLA
- Oversaw design, construction and operation of $50M manufacturing plant supporting Cell Banking, Drug Substance and Drug Product
- Extensive global experience with 10+ CMOs serving as Technical lead to Steering Committee lead, spanning early development through to commercial supply programs

FDA and International Regulatory Submissions

- Critical contributions to 15 successful INDs and 3 BLAs for new biological entities
- Active participant in 15 face to face health authority meetings including pre-IND, EOP2, pre-BLA and BLA mid and late cycle
- FDA audits – Rigorously prepared for and navigated 5 successful Pre-Approval Inspections
- Presented at FDA Advisory Committee meeting in support of Product Approval

Success in a Variety of Corporate Cultures

- Founder and CEO: novel Joint Venture (CTMC)
- Startup: 5th employee in spinoff/startup Biotech (CoGenesys) and drove 3 INDs in first 12 months
- Midsize Biopharma: differentiating project contributions as company grew from 500 to 1000 (HGS)

- Biologics leader in large Pharma: Drove Biologics from a novelty to primary corporate growth engine within largest generics company in the world headquartered in Israel (Teva)
- Leadership position in academic cancer research center (MD Anderson)

Experience on both sides of Due Diligence and Partnerships

- Primary representative (CMC) for out-licensing 8 assets
- Primary representative (CMC) for evaluation of in-licensing 15+ assets
- Alliance lead for project partnered with GSK

EXPERIENCE:

Founder and Chief Executive Officer, CTMC, Houston, TX 2022-current

Conceived and founded a novel Joint Venture between National Resilience and MD Anderson Cancer Center by spinning the Biologics Development group (65 FTEs) out of MDACC into a stand alone company. Our mission is to accelerate impactful cell therapies reaching patients. We accomplish this by synergizing industrial therapeutics development and manufacturing with the #1 oncology clinical center. We develop both MDACC and Biotech invented therapeutics with a novel business model that defines a new category.

Vice-President, Biologics Development, MD Anderson, Houston, TX 2019-2022

Established a biotech within MD Anderson to select and develop novel mAbs and cell therapies for cancer. Built an organization to work closely with academic and translational researchers, while establishing a new paradigm for the development of biologics. Acquired a 60,000 sq ft cell therapy development and manufacturing facility, started up operations, built a team of 65, created a portfolio of MDACC and Biotech invented cell therapies.

Vice-President, Biologics CMC
Site Head, Specialty R&D, Teva Pharmaceuticals, West Chester, PA 2014-2019

Key leader in driving strategic change within the company to transition from a generics focused portfolio to Biologics driven pipeline. Responsible for all BioPharmaceutical CMC development efforts through 170 FTEs. This encompassed both early stage development activities through commercial readiness utilizing both internal and external manufacturing sources. Led change through a significant consolidation of biologics development sites to new center for biologics development. Oversaw investments of $100M and hiring of 100+. Led integrated site of 600.

Sr Director, Site Head, Teva Biopharmaceuticals, Rockville, MD 2008-2014
Site Head (100 FTEs), directing Biologics Development. Responsible for all CMC deliverables resulting in 8 INDs and 2 BLAs.

Director, Pharmaceutical Development, CoGenesys, Rockville, MD 2006-08
Selected as 5th employee to join initial spinoff from Human Genome Sciences. Direct oversight of Pharmaceutical Development and matrix oversight of all CMC activities. Grew group to 65 before acquisition by Teva.

Sr Scientist, Process Dev, Human Genome Sciences, Rockville, MD 2001-06
Advanced through Preclinical Discovery, Lead Development and Characterization and Process Development Departments. Acted as HGS team leader for partnership with GSK on $183 million Syncria project.

EDUCATION:

Stanford University, School of Medicine
PhD in Molecular and Cellular Physiology, 2000
Richard Scheller's lab. Combined bioinformatical, molecular, cellular, biochemical and structural approaches to study the molecular mechanisms of vesicle trafficking.

Massachusetts Institute of Technology
BS in Biology, 1994

SELECT PUBLICATIONS:

Misura KM, **Bock JB**, Gonzales LC Jr., Scheller RH, Weis WI. Three-dimensional structure of the amino-terminal domain of syntaxin 6, a SNAP-25 C homolog. Proceedings of the National Academy of Sciences, July 9, 2002 99(14) 9184-9.

Bock JB, Matern H, Peden AA, and Scheller RH. A genomic perspective on the role of SNAREs in the organization of membrane compartments. Nature 409, 839-841 15 February 2001.

Scales SJ, **Bock JB**, Scheller RH. The specifics of membrane fusion. Nature. 2000Sep14; 407(6801):144-6.

Bock, JB and Scheller, RH. SNAREs mediate lipid bilayer fusion**.** Proceedings of the National Academy of Sciences. Oct 26, 1999;96(22):12227-9.

Bock JB, Klumperman J, Davanger S, Scheller RH. Syntaxin 6 functions in trans-Golgi network vesicle trafficking. Molecular Biology of the Cell. 1997 Jul;8(7):1261-71.

Bock JB, Scheller RH. Protein transport: A fusion of new ideas. Nature. 1997 May 8;387:133-5.